CFM
AEON icon

Catalyst Funds Management’s AEON Biopharma AEON Stock Holding History

Catalyst Funds Management’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4
Closed -$3.31K – 1153
2024
Q1 		$3.31K Buy
+4
New +$2.9K ﹤0.01% 1021

Other funds holding AEON

ACM
Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Catalyst Funds Management's AEON Position: Q2 2024 in Review

Catalyst Funds Management sold out of AEON Biopharma (AEON) in Q2 2024, closing a stake of 4 shares — an estimated $3.31K sold.

Catalyst Funds Management first reported a position in AEON in Q1 2024 and held it in 1 quarter. The position peaked at $3.31K in Q1 2024. 24 funds tracked by Wall St. Rank hold AEON as of Q2 2024.

  • Catalyst Funds Management reported no remaining AEON Biopharma position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 4 AEON Biopharma shares in Q2 2024, an estimated $3.31K.
  • Catalyst Funds Management first reported a position in AEON Biopharma in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's AEON Biopharma position peaked at $3.31K in Q1 2024.
  • 24 funds tracked by Wall St. Rank held AEON Biopharma as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.